Tislelizumab News
Tislelizumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Tislelizumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Non-small cell lung cancer (NSCLC) Tevimbra, in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, is indicated for...
- Evidence level: L5
- Predicted indications (20):
- mixed-type autoimmune hemolytic anemia (93.8%)
- idiopathic aplastic anemia (93.8%)
- dermatitis (93.7%)
- paroxysmal nocturnal hemoglobinuria (93.7%)
- drug-induced autoimmune hemolytic anemia (93.7%)
- proteinuria (93.1%)
- acne keloid (93.0%)
- neonatal autoimmune hemolytic anemia (93.0%)
- primary CD59 deficiency (92.8%)
- amyopathic dermatomyositis (92.8%)
- neonatal dermatomyositis (92.7%)
- cold agglutinin disease (92.5%)
- hydroa vacciniforme, familial (92.4%)
- secondary interstitial lung disease specific to childhood associated with a connective tissue disease (92.4%)
- acrodermatitis chronica atrophicans (92.2%)
- hepatic veno-occlusive disease-immunodeficiency syndrome (91.7%)
- pancytopenia due to IKZF1 mutations (91.0%)
- chromhidrosis (91.0%)
- adult idiopathic neutropenia (90.8%)
- congenital neutropenia-myelofibrosis-nephromegaly syndrome (90.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.